EGFR and neoplasm: We conducted a pre-clinical study to evaluate the anti-tumor activity of theliatinib in a panel of patient derived esophageal cancer xenograft (PDECX) models to determine the association between anti-tumor activity of theliatinib and different levels of EGFR expression in EC tumors.